EUVIMEDEUVIMED entdecken
Crossref

Identify new pseudogene RPL7P1-oriented network as a drug target against infections pre-existing diabetes

Jiajun Chen, Chenxi Li, Ying Wang, Shiwei Chen, Xiangqi Li iD

Integrative Biology · 2025

DOI: 10.1093/intbio/zyaf015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Integrative Biology, 2025. Verfasst von Jiajun Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, No. 516 Jungong Road, Shanghai 200093, China. Hauptthemen laut MEDLINE: Pseudogenes, Ribosomal Proteins, Gene Regulatory Networks, Diabetes Mellitus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Pudong New Area Science and Technology Commission of Shanghai, Key Specialty Construction Project of Pudong Health Bureau of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes coexisting with infections (DCI) significantly increases the risk of severe outcomes and mortality in patients. This study proposes that RPL7P1, an uncharacterized pseudogene, plays a role in the pathogenesis of DCI.

Methods

Using a multifaceted approach, we employed experimental datasets from ENCODE to identify key genes. Drug repositioning was performed using gene network analysis with z-scores and the ROCR package. Network expansion was facilitated by NetworkAnalyst's core algorithms, with disease validation through the NHGRI GWAS Catalog. Cytoscape was utilized for network visualization.

Results

Our findings reveal RPL7P1's potential involvement in DCI through modulation of CBL and STXBP3 by sequestering hsa-miR-144-3p, interaction with IGF2BP2 protein, and crosstalk with ATP6V1E1 RNA. Single-cell profiling pinpointed endothelial cells as a potential signaling nexus. Therapeutic agents targeting the RPL7P1-centric network showed promise in managing infections in diabetic patients. Additionally, we identified key molecular players, the m6A modification of RPL7P1, and its role in cuproptosis—a novel form of cell death.

Conclusion

This research elucidates the potential role of the novel pseudogene RPL7P1 in DCI, highlighting the importance of pseudogenes in complex diseases and providing novel insights into the epigenetic modulation of diabetes complicated by infections. Insight Box Diabetes and infections often coexist, complicating our understanding of their shared mechanisms. To address this, we employed a comprehensive suite of bioinformatics methods, including pathway mapping, ceRNA analysis, PPI evaluation, single-cell dissection, network modeling, and drug repositioning strategies. Our research revealed that RPL7P1 modulates signaling pathways by sponging miR-144-3p, interacting with IGF2BP2 and ATP6V1E1 RNA, and influencing cuproptosis—a novel form of cell death—through m6A modification, a key RNA modification. We identified endothelial cells as key mediators of the RPL7P1 network in the liver. Additionally, our integrative approach uncovered five potential therapeutic drugs targeting the RPL7P1 network. These findings provide novel insights into coexisting diabetes and infections, underscoring the value of multidisciplinary strategies in uncovering coexisting disease mechanisms and treatment opportunities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PseudogenesRibosomal ProteinsGene Regulatory NetworksDiabetes MellitusHumansMicroRNAsRNA-Binding ProteinsSignal TransductionDrug RepositioningComputational Biology

Stichwörter der Autor:innen

RPL7P1comorbiditydiabetesdruginfectionpseudogenesingle-cell

Substanzen

MicroRNAsRibosomal ProteinsRNA-Binding ProteinsIGF2BP2 protein, human

Autor:innen und Institutionen

  • School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, No. 516 Jungong Road, Shanghai 200093, China.
  • Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Gongli Hospital, Shanghai University of Medicine & Health Sc…
  • Department of Intervention, Gongli Hospital, Shanghai University of Medicine & Health Sciences, No. 219 Miaopu Road, Pudong New Area, Shanghai 200135, China.
  • Department of Endocrinology and Metabolism, Gongli Hospital, Shanghai University of Medicine & Health Sciences, No. 219 Miaopu Road, Pudong New Area, Shanghai 200135, China.

ORCID-Profile: Xiangqi Li

Förderung

  • Pudong New Area Science and Technology Commission of Shanghai
  • Key Specialty Construction Project of Pudong Health Bureau of Shanghai

Zitieren

APA

Chen, J., Li, C., Wang, Y., Chen, S., & Li, X. (2025). Identify new pseudogene RPL7P1-oriented network as a drug target against infections pre-existing diabetes. Integrative Biology. https://doi.org/10.1093/intbio/zyaf015

Vancouver

Chen J, Li C, Wang Y, Chen S, Li X. Identify new pseudogene RPL7P1-oriented network as a drug target against infections pre-existing diabetes. Integrative Biology. 2025. doi:10.1093/intbio/zyaf015

BibTeX
@article{Chen2025,
  author = {Chen, Jiajun and Li, Chenxi and Wang, Ying and Chen, Shiwei and Li, Xiangqi},
  title = {Identify new pseudogene RPL7P1-oriented network as a drug target against infections pre-existing diabetes},
  journal = {Integrative Biology},
  year = {2025},
  doi = {10.1093/intbio/zyaf015}
}
Kostenlos starten →